切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜泌尿外科杂志(电子版)

中华腔镜泌尿外科杂志(电子版) ›› 2018, Vol. 12 ›› Issue (05) : 352 -355. doi: 10.3877/cma.j.issn.1674-3253.2018.05.015

所属专题： 文献；

实验研究

表达甲酰辅酶A转移酶的大肠杆菌对大鼠尿草酸浓度的影响
赖德辉1,†(), 李名钊2, 盛明1, 李逊1, 何永忠1, 李天1, 徐桂彬1, 杨炜青1   
  1. 1. 510700　广州医科大学附属第五医院泌尿外科；510700　广州医科大学附属第五医院微创新技术和产品转化中心
    2. 510630　广州，中山大学附属第三医院泌尿外科
  • 收稿日期:2018-01-04 出版日期:2018-10-01
  • 通信作者: 赖德辉
  • 基金资助:
    广州医科大学博士启动项目(2014C40)

Probiotic administration of Escherichia coli Nissle 1917 with FCoAT expression reduces urinary oxalate in rat model

Dehui Lai1,†(), Mingzhao Li2, Xun Li1, Yongzhong HE1, Tian Li1, Guibin Xu1, Weiqing Yang1   

  1. 1. Department of Urology, the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 510700, China; Minimally Invasive Technique and Product Translational Center, Guangzhou Medical University, Guangzhou 510700, China
    2. Department of Urology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
  • Received:2018-01-04 Published:2018-10-01
  • Corresponding author: Dehui Lai
  • About author:
    Corresponding Author: Dehui Lai, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

赖德辉, 李名钊, 盛明, 李逊, 何永忠, 李天, 徐桂彬, 杨炜青. 表达甲酰辅酶A转移酶的大肠杆菌对大鼠尿草酸浓度的影响[J]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(05): 352-355.

Dehui Lai, Mingzhao Li, Xun Li, Yongzhong HE, Tian Li, Guibin Xu, Weiqing Yang. Probiotic administration of Escherichia coli Nissle 1917 with FCoAT expression reduces urinary oxalate in rat model[J]. Chinese Journal of Endourology(Electronic Edition), 2018, 12(05): 352-355.

目的

探讨喂饲表达甲酰辅酶A转移酶（FCoAT）的大肠杆菌Nissle1917（EcN-Frc）对大鼠尿草酸浓度的影响。

方法

将30只雄性SD大鼠随机分为六组（编号A-F），每组5只。除A组外，其余五组在食物中每克添加1%草酸。B组每次喂食前30 min，喂食1 ml EcN-Frc培养液，C、D、E、F组喂食1 ml EcN-Frc悬液（活细菌数103）。C、D、E、F组喂饲细菌的方式分别为每日1次，每3 d一次，每周一次和观察期内首日喂养一次。实验周期为2周，分别于喂养当日，喂养后3、6、9、14 d分别记录大鼠健康情况和24 h尿草酸排泄量。

结果

口服ECN-Frc能有效减低高草酸饮食大鼠的24 h尿草酸排泄量。含103活菌数的EcN-Frc在喂养后3 d即可发挥作用。1次喂服103个活菌数的ECN-Frc，2周后仍能有效降低大鼠尿中草酸浓度。所有大鼠观察期内均体健，未见明显异常。

结论

低剂量口服EcN-Frc能有效降低高草酸饮食大鼠的24 h尿草酸排泄量，且安全，耐受性好。

关键词: 酶, 大肠杆菌, 草酸, 治疗, 大鼠, 随机
Objective

To study of using E.coli Nissle1917 which can express FCoAT (EcN-Frc) as probiotic treatment to reduce urine oxalate in a rat model.

Methods

Thirty male SD rats were randomly divided into 6 groups (A to F). 1% oxalate was added to the diet for rats in group B, C, D, E, F; while rats in group A received regular diet. Furthermore, 30 minutes before each feeding, each rats in group B received 1 ml suspension, while those in group C, D, E, F was given 1 ml EcN-Frc suspension (103 viable bacteria). Rats in group C, D, E, F were feeding bacteria every day, once every three days, once a week, respectively. 24-hour urine specimens were obtained on days 0, 3, 6, 9, 14 by placing the rats in metabolic cages.

Results

Hyperoxaluria rats due to high dietary oxalate were treated by EcN-Frc. It can effectively reduce the high urinary oxalate level in rat model since day 3 after supplementation. The effect of the decrease proved directly proportional to the dose of EcN-Frc.But, one dose of EcN-Frc (103 viable bacteria) can still effectively reduce urinary oxalate in a 2 weeks period. It showed that EcN-Frc had the ability to stay stable in rat’s intestine and grew well. In addition, during 2 weeks period, all rats kept health with no signs of toxicity.

Conclusions

Probiotic administration of low dose EcN-Frc can effectively reduce the high urinary oxalate in hyperoxaluria rats. EcN-Frc can stay stable in rat’s intestine and play a role in degrading oxalate. This approach appears to be safe and good tolerance.

Key words: FCoAT, E.coli, Oxalate, Treatment, Rat, Random
表1 喂饲EcN-Frc对高草酸尿大鼠24 h尿草酸排泄的影响[±s（min-max）]
组别 24 h尿草酸量（μmol）
0 3 d 6 d 9 d 14 d
A组 2.52±0.61(1.74-3.12) 2.86±0.54(2.14-3.61)0 2.39±0.41(1.96-3.32)0 2.64±0.82(1.62-4.1)00 2.83±0.91(1.12-4.31)0
B组 3.11±0.53(2.21-4.35) 8.26±2.31(5.61-11.35) 10.2±2.13(6.42-12.63) 10.5±2.31(7.06-11.31) 10.2±1.93(9.21-13.25)
C组 3.34±0.47(2.14-4.52) 7.27±1.25(5.80-10.24) 8.13±1.78(6.12-10.45) 8.33±1.47(5.92-9.24)0 8.67±1.58(6.34-10.24)
D组 3.61±0.68(2.22-4.57) 8.04±2.24(5.68-11.24) 8.77±1.36(6.96-9.62)0 8.44±1.24(5.63-10.42) 9.15±1.69(6.14-10.23)
E组 3.42±0.82(2.03-4.81) 7.53±1.71(5.37-10.67) 9.07±0.94(7.21-11.20) 8.57±1.68(6.34-11.23) 8.43±1.75(6.24-11.37)
F组 3.56±0.74(2.54-4.53) 8.14±1.26(5.63-10.14) 9.94±2.72(8.32-12.16) 8.22±2.14(6.34-11.25) 8.67±2.42(7.14-11.26)
表2 喂饲EcN-Frc对高草酸尿大鼠平均体重的影响[±s（min-max）]
组别 体重（g）
0 3 d 6 d 9 d 14 d
A组 187.45±25.61 (168.34-196.51) 202.86±32.54 (182.14-236.61) 232.39±36.41 (211.96-280.32) 262.64±30.82 (221.52-304.13) 281.23±32.91 (242.34-319.43)
B组 183.11±21.53 (162.45-194.35) 208.26±32.31 (195.61-241.39) 230.2±32.13 (196.42-272.63) 250.65±32.31 (227.06-291.31) 283.12±41.93 (259.21-320.41)
C组 188.44±20.47 (158.14-200.52) 207.27±41.25 (195.47-250.59) 228.13±31.78 (198.12-260.45) 255.33±31.47 (235.92-299.28) 268.34±50.58 (249.13-319.67)
D组 173.61±21.68 (162.22-203.57) 208.04±42.24 (194.68-231.24) 226.77±32.36 (196.96-259.62) 243.84±35.24 (225.63-298.42) 270.45±50.23 (230.12-324.12)
E组 189.42±28.82 (153.03-214.81) 197.53±41.53 (185.37-230.67) 229.07±20.94 (197.21-250.20) 238.57±24.68 (226.34-291.23) 288.43±21.75 (261.24-311.37)
F组 188.56±25.74 (168.54-213.53) 218.14±45.26 (165.63-251.14) 229.44±18.72 (199.25-256.36) 248.22±22.14 (226.34-281.25) 278.67±32.42 (267.14-311.26)
[1]
赖德辉，李逊，雷鸣, 等. 克隆与表达产甲酸草酸杆菌代谢基因Frc及临床意义[J]. 中华腔镜泌尿外科杂志(电子版), 2010, 4(3):239-244.
[2]
赖德辉，李逊，雷鸣, 等. 基因工程构建表达融合蛋白GST-FCoAT的益生大肠杆菌EcN-Frc[J]. 实用医学杂志, 2010, 26(24):4480-4482.
[3]
Sidhu H, Schmidt ME, Cornelius JG, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes:possible prevention by gut recolonization or enzyme replacement therapy[J]. J Am Soc Nephrol, 1999, 10 Suppl 14:S334-40.
[4]
Sidhu H, Allison MJ, Chow JM, et al. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes[J]. J Urol, 2001, 166(4):1487-1491.
[5]
Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp. Reduces urinary oxalate excretion by promoting enteric oxalate secretion[J]. Kidney Int, 2006, 69(4):691-698.
[6]
Hoppe B, Beck B, Gatter N, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1[J]. Kidney Int, 2006, 70(7):1305-1311.
[7]
Dobrindt U, Hochhut B, Hentschel U, et al. Genomic islands in pathogenic and environmental microorganisms[J]. Nat Rev Microbiol, 2004, 2(5):414-424.
[8]
Grozdanov L, Zähringer U, Blum-Oehler G, et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917[J]. J Bacteriol, 2002, 184(21):5912-5925.
[9]
Sun J, Gunzer F, Westendorf AM, et al. Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data[J]. J Biotechnol, 2005, 117(2):147-161.
[10]
Grozdanov L, Raasch C, Schulze J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917[J]. J Bacteriol, 2004, 186(16):5432-5441.
[1] 张伟. 牙及牙槽外科：舒适治疗的先锋[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 386-388.
[2] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[3] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[4] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[5] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[6] 许丁伟, 马江云, 李新成, 黄洁. Alagille综合征疑诊为先天性胆道闭锁一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 681-687.
[7] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[8] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[9] 毛宁, 徐文婷, 朱勇. 孟德尔随机化探索雄性激素水平与肛周脓肿的关系[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 490-494.
[10] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[11] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[12] 王飞飞, 王光林, 孟泽松, 李保坤, 曹龙飞, 张娟, 周超熙, 丁源一, 王贵英. 敲低IMPDH1对结肠癌SW480、HT29细胞生物功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(08): 884-890.
[13] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[14] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号